Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin for exercise capacity in heart failure and diabetes
jRCTs031220712Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of imeglimin in heart failure (HF) and diabetes mellitus (DM) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Change in peak oxygen consumption. Started Jun 2023; status: recruiting.
02
Drugs
imeglimin
03
Conditions
heart failure (HF)diabetes mellitus (DM)
Beyond the preview
Go deeper on jRCTs031220712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220712.